ArticleCureus2025
A Report on the Use of Biparametric MRI in Prostate Cancer Diagnosis: A Two-Year Single Centre Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of pre-biopsy MRI scans is now a standard of care in the evaluation of men with elevated prostate-specific antigen (PSA); however, the use of biparametric MRI (bpMRI) has been a source of controversy amongst health professionals. The study aimed to analyse our experience with the use of bpMRI in evaluating suspected prostate cancer in conjunction with other clinical indicators, such as PSA density (PSAD) and family history of prostate cancer.
methodsThis retrospective, single-centre study consisted of 404 patients who had an MRI due to elevated PSA and subsequent prostate biopsies.
resultThe average age of the study population was 69.7±7.3 years, with the majority of the patients above 70 years. A statistically significant positive correlation was observed between PSAD and Prostate Imaging-Reporting and Data System (PI-RADS) scores (r=0.2, p<0.001). Higher PSAD groups showed an increased proportion of PI-RADS 4 and 5 lesions. There was a significant positive correlation (r=0.2, p<0.001) between PSAD and International Society of Urological Pathology (ISUP) grade, indicating that the detection of clinically significant and higher-grade prostate cancer increases with PSAD. High-risk prostate cancers (ISUP grades 4 and 5) were detected in the high-risk category of PSAD (14.6% and 18%, respectively). PI-RADS scores correlated significantly with ISUP grades (r=0.3, p<0.001). Conclusion: Our study demonstrated that bpMRI-detected PI-RADS scores significantly correlated with PSAD, histological diagnosis (ISUP grade), and clinically significant prostate cancer detection. bpMRI has a role in the diagnostic value of prostate cancer when combined with PSAD and a family history of prostate cancer. It is effective in detecting clinically significant prostate cancers at a lower cost and shorter time while eliminating the potential harm of the use of gadolinium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.